December 2, 2021
Supporting Innovative Biotechs to Bring Cell and Gene Therapies to Market
Philip Gialenios, Former President and Chief Operating Officer
Kineticos takes an immersive stance with our biotech engagements and investments, working closely in a collaborative effort with key leadership roles in the cell and gene therapy companies we support. By advising emerging organizations on all phases of the life cycle and helping them succeed through commercialization and beyond, Kineticos and our clients benefit from a return on their investments through equity growth while contributing to improved patient outcomes. With our ultimate goal of playing an impactful role in developing cures for cancer and rare diseases, we leverage our highly experienced and knowledgeable team to partner with organizations most likely to positively impact patient health.
Philip Gialenios, former President and Chief Operating Officer of Kineticos Life Sciences, met with Pharma’s Almanac Editor-in-Chief David Alvaro to explain how Kineticos is helping to advance novel therapies by having its consulting advisors work directly with cell and gene therapy companies and offering potential support through its investment activities to identify, establish, and execute effective growth strategies.
Read their full conversation here: Supporting Innovative Biotechs to Bring Cell and Gene Therapies to Market